

# Lin Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8137633/publications.pdf>

Version: 2024-02-01

30  
papers

3,477  
citations

304743

22  
h-index

477307

29  
g-index

30  
all docs

30  
docs citations

30  
times ranked

6598  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic Pan-Cancer Characterization of Nuclear Receptors Identifies Potential Cancer Biomarkers and Therapeutic Targets. <i>Cancer Research</i> , 2022, 82, 46-59.	0.9	3
2	Systematic illumination of druggable genes in cancer genomes. <i>Cell Reports</i> , 2022, 38, 110400.	6.4	14
3	Endothelial plasticity drives aberrant vascularization and impedes cardiac repair after myocardial infarction. , 2022, 1, 372-388.		9
4	Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. <i>Nature Cancer</i> , 2021, 2, 83-97.	13.2	56
5	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. <i>Nature Communications</i> , 2021, 12, 3424.	12.8	74
6	Targeting the transcription cycle and RNA processing in cancer treatment. <i>Current Opinion in Pharmacology</i> , 2021, 58, 69-75.	3.5	1
7	The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. <i>Nature Cancer</i> , 2021, 2, 1406-1422.	13.2	33
8	Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. <i>Nature Communications</i> , 2020, 11, 1293.	12.8	196
9	Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. <i>PLoS Genetics</i> , 2020, 16, e1008641.	3.5	78
10	Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2 $\beta$ . <i>Nature Communications</i> , 2018, 9, 559.	12.8	176
11	Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	180
12	Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. <i>Molecular and Cellular Biology</i> , 2016, 36, 2742-2754.	2.3	42
13	Detection of Long Noncoding RNA Expression by Nonradioactive Northern Blots. <i>Methods in Molecular Biology</i> , 2016, 1402, 177-188.	0.9	5
14	Characterization of Long Noncoding RNA-Associated Proteins by RNA-Immunoprecipitation. <i>Methods in Molecular Biology</i> , 2016, 1402, 19-26.	0.9	16
15	Effects of BRCA1/2 on Ovarian and Breast Cancer Survival Response. <i>Clinical Cancer Research</i> , 2015, 21, 3807-3807.	7.0	5
16	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. <i>Cancer Cell</i> , 2015, 28, 529-540.	16.8	601
17	Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis. <i>Clinical Cancer Research</i> , 2015, 21, 211-220.	7.0	165
18	A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer. <i>Cancer Cell</i> , 2014, 26, 344-357.	16.8	361

#	ARTICLE	IF	CITATIONS
19	Lin-28 Homologue A (LIN28A) Promotes Cell Cycle Progression via Regulation of Cyclin-dependent Kinase 2 (CDK2), Cyclin D1 (CCND1), and Cell Division Cycle 25 Homolog A (CDC25A) Expression in Cancer. <i>Journal of Biological Chemistry</i> , 2012, 287, 17386-17397.	3.4	60
20	Genomic DNA Copy-Number Alterations of the let-7 Family in Human Cancers. <i>PLoS ONE</i> , 2012, 7, e44399.	2.5	44
21	Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers. <i>PLoS ONE</i> , 2010, 5, e10277.	2.5	362
22	Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation. <i>PLoS ONE</i> , 2009, 4, e4295.	2.5	30
23	Expression profile of microRNA in epithelial cancer: diagnosis, classification and prediction. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 25-36.	1.6	4
24	Therapeutic MicroRNA Strategies in Human Cancer. <i>AAPS Journal</i> , 2009, 11, 747-57.	4.4	153
25	MicroRNA epigenetic alterations in human cancer: One step forward in diagnosis and treatment. <i>International Journal of Cancer</i> , 2008, 122, 963-968.	5.1	84
26	Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7004-7009.	7.1	491
27	Transcriptional Regulation of PIK3CA Oncogene by NF- $\kappa$ B in Ovarian Cancer Microenvironment. <i>PLoS ONE</i> , 2008, 3, e1758.	2.5	41
28	Integrative Genomic Analysis of Phosphatidylinositol 3-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5314-5321.	7.0	111
29	miRNA genetic alterations in human cancers. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1375-1386.	3.1	50
30	MicroRNAs: A New Insight into Cancer Genome. <i>Cell Cycle</i> , 2006, 5, 2216-2219.	2.6	32